Adult Psychiatry· 22 min read
FDA Testosterone Idiopathic Hypogonadism: What the April 2026 Step Means for Men With Low Libido
Published: April 2026 | By: Dr. Baghel
On April 16, 2026, the U.S. Food and Drug Administration announced it is encouraging holders of approved testosterone replacement therapy (TRT) products to pursue a new indication: treatment of low libido in men with idiopathic hypogonadism. The agency set an April 30, 2026 deadline for sponsors to contact FDA regarding submission of a supplemental New Drug Application. This is a regulatory signal, not an approval. No man can be prescribed TRT today for an indication that does not yet exist on a label, and no clinician should change practice on the basis of an announcement alone. The significance is in the direction of travel.
What the current label actually permits, and what it doesn’t, is covered on my TRT telehealth page.
For men in North Carolina who have been told their testosterone is “low normal” or that their lab numbers do not technically qualify them for TRT despite real symptoms, the FDA testosterone idiopathic hypogonadism announcement matters. Over the next two to four years, the regulatory landscape that defines who is and is not a candidate for testosterone therapy is likely to shift. This article explains what the FDA actually did, what idiopathic hypogonadism is, what the evidence base looks like, what did not change on April 16, and what a sound clinical workup looks like in the meantime.
Update: July 15, 2026, The Pentagon Adds Testosterone Screening to Military Physicals
On July 15, 2026, Defense Secretary Pete Hegseth announced that the military will begin screening service members age 30 and older for low testosterone as part of their routine physicals. Reporting from the Associated Press and PBS NewsHour indicates the screening applies to men, and the Pentagon did not answer questions about women. Those who screen positive are offered treatment and can decline it. For troops under 30, the screening itself is voluntary.
It’s the same theme as the FDA news above, showing up in a different institution. The people who decide who gets tested and treated for low testosterone are widening the gate.
My read runs against most of the coverage. The instinct behind this policy is closer to right than wrong. The age-30 cutoff has no good data behind it, and I’ll come back to it. But the deeper instinct holds up. Waiting for a man to walk in and recite the textbook symptoms is a poor way to catch the men who are actually deficient, because the textbook symptoms are the ones that overlap with everything else.
The military is responding to a specific problem. The complaints that send a man to a doctor, or to me, are fatigue, low mood, poor concentration, and low drive. Those are common, and they are not specific to low testosterone. The European Male Aging Study followed 3,369 men and found that the only symptoms that track with a low testosterone level are sexual: reduced morning erections, low libido, and erectile difficulty (PMID 20554979). When the researchers required those sexual symptoms alongside a confirmed low level, late-onset hypogonadism showed up in about 2 percent of men. Fatigue and low mood, on their own, pointed almost nowhere.
That cuts two ways, and both land in my office. Symptom-only evaluation misses men who have a deficiency but show up with the vague complaints instead of the classic sexual ones. It also mislabels tired, low men who have perfectly normal testosterone and a different problem, often depression.
When a patient asks whether men should get their testosterone checked more readily, my answer is yes, with one condition. Check it properly. A single random afternoon draw tells you very little, because testosterone runs on a daily rhythm and swings from day to day. What matters is a fasting morning total testosterone drawn before 10 a.m., interpreted with free testosterone, LH, and FSH when the picture calls for it (PMID 29562364). The Endocrine Society recommends confirming a low value with a second morning test. In practice, a well-timed morning level and a clear clinical story are usually enough for me to act on, and I repeat when the number is borderline or doesn’t fit. Where I diverge from the guideline is the threshold to order that first test, and I set it lower, especially for men who come in depressed.
The overlap with depression is where I spend most of my time. Low testosterone and depression run together more than either field likes to admit. Men with depression carry higher rates of low testosterone, and the symptoms blur into each other. Testosterone is not an antidepressant. A 2019 meta-analysis in JAMA Psychiatry found only a small drop in depressive symptoms, and the effect was larger at higher doses (PMID 30427999). For a man whose low mood, flat energy, and low drive come with a low, confirmed level, treating the deficiency can help the depressive symptoms. Missing it means treating half the problem.
My prediction, and I’ll label it as a prediction, is that this doesn’t stay in the military. The month before the Pentagon moved, the FDA proposed loosening testosterone’s labeling for age-related low levels, which I covered in the update above. Put those together and the direction is clear enough. Testing testosterone is going to become a more routine part of men’s healthcare over the next few years, the way cholesterol did. Whether that’s good depends entirely on how it’s done. Done right, with a proper workup, it finds men who are deficient and treatable. Done as a single number and a reflex prescription, it medicalizes ordinary aging and puts men on a drug they don’t need, with effects on mood and behavior of its own.
If you’re in North Carolina, whether veteran or civilian, and the headlines made you wonder about your own levels, that’s a fair question to bring to a proper evaluation. If you’re active duty, your testing now runs through military medicine. Take the question to your own providers, and read this as background on where the policy is heading. The advice that matters most is the least dramatic one: get it worked up properly before anyone hands you a vial.
Update: June 18, 2026, the FDA requests the label changes
Two months after the April step, the FDA followed through. On June 18, 2026, it asked drugmakers to change the labels on testosterone products. This is the next move in the regulatory process described below.
There are three changes. First, the FDA removed the 2015 limitation of use, which stated that testosterone’s benefit had not been established in men with age-related low testosterone. Second, it narrowed the prostate cancer contraindication to men with metastatic prostate cancer, where the old label had warned against any known or suspected prostate cancer. Third, it eased the warning about enlarged prostate, keeping closer monitoring only for men with severe symptoms (FDA labeling change).
The basis is the same TRAVERSE evidence covered below: no meaningful rise in heart attack or stroke. The practical effect is that more doctors will feel comfortable prescribing testosterone for men with real symptoms and confirmed low levels.
What still has not changed: testosterone remains a Schedule III controlled substance, and a careful workup still comes first. If you want the full picture of how I evaluate and treat low testosterone, see my complete guide to testosterone therapy for North Carolina men.
What the FDA Actually Announced on April 16, 2026
The FDA’s press release describes a narrow, procedural action. The agency reviewed published clinical trial evidence and the conclusions of a December 2025 expert panel on testosterone replacement therapy, then formally invited drug sponsors of approved TRT products to contact the agency about pursuing an expanded indication. The proposed new indication is specific: treatment of low libido in men with decreased libido associated with idiopathic hypogonadism.
The procedural mechanism is a supplemental New Drug Application (sNDA). Sponsors who already hold approved TRT NDAs (for products such as testosterone gels, transdermal patches, and injectable formulations) would submit additional clinical data to support the new use. The FDA published a parallel notice in the Federal Register on April 20, 2026, under Docket No. FDA-2025-N-6743, asking sponsors to make initial contact by April 30, 2026.
FDA Commissioner Marty Makary framed the announcement as a response to “new and emerging data” suggesting an opportunity to help men whose symptoms significantly affect quality of life. Brian J. Christine, MD, Assistant Secretary for Health, called sexual health an important component of overall well-being. Both men were careful to add that any approval would still require demonstration of substantial evidence of effectiveness and a favorable benefit-risk profile. In other words, the door is open, but the evidentiary burden has not changed.
What this announcement is not: it is not an approval of TRT for low libido. It is not a change to current prescribing guidelines. It is not a green light for any clinician to prescribe testosterone outside currently approved indications. It is the start of a regulatory pathway that, if sponsors respond and submit adequate data, could result in an approved indication in the coming years.
What Is Idiopathic Hypogonadism, and Why Does the Word “Idiopathic” Matter Here?
Hypogonadism is the clinical state of low testosterone production. It is conventionally divided into two categories based on where the problem lies. Primary hypogonadism reflects a defect at the testes themselves. Secondary hypogonadism reflects a defect in the hypothalamus or pituitary gland, the brain structures that signal the testes to make testosterone. The current FDA-approved indication for TRT covers men with hypogonadism tied to specific structural or genetic causes. Examples include Klinefelter syndrome, pituitary tumors, prior chemotherapy or radiation, and traumatic testicular injury.
Idiopathic hypogonadism describes men who have low serum testosterone and clinical symptoms but no identifiable structural, genetic, or disease-based cause. Their hypothalamus appears normal. Their pituitary appears normal. Their testes appear normal. Yet their testosterone is low and they have symptoms consistent with that finding. This is the population the FDA is now signaling may eventually qualify for an approved indication.
This category overlaps substantially with what is sometimes called age-related hypogonadism or late-onset hypogonadism, though the diagnostic terms are not interchangeable. The Endocrine Society’s 2018 Clinical Practice Guideline distinguishes between organic hypogonadism (with a known cause) and functional hypogonadism (related to obesity, medical comorbidities, or aging). The current standard of care in those functional cases prioritizes treating the underlying contributor, such as weight loss, sleep apnea management, or medication review, before considering testosterone therapy.
The clinical reality is that many men present with the symptom pattern (low libido, fatigue, low mood, reduced morning erections, decreased motivation) and confirmed low total testosterone on repeated morning measurements, but a workup that finds no identifiable cause. Until the FDA expands the indication, prescribing TRT to this group is technically off-label. In practice, this happens routinely, but it sits in a regulatory gray zone that has implications for insurance coverage, prescriber liability, and the standard of care.
What the Evidence Actually Shows: The TRAVERSE Trial
The FDA’s preliminary review of “rigorous, well-controlled clinical trials” almost certainly draws heavily on the TRAVERSE study and its sexual function substudy. TRAVERSE enrolled 5,204 middle-aged and older men with hypogonadism and either established cardiovascular disease or elevated cardiovascular risk. The primary trial published in the New England Journal of Medicine in 2023 found that testosterone replacement therapy was noninferior to placebo for major adverse cardiovascular events, addressing a longstanding safety concern that had constrained TRT prescribing since the early 2010s [1].
Nested within TRAVERSE was a sexual function study of 1,161 men who had low libido at baseline. Participants were randomized to testosterone gel 1.62 percent or placebo gel and followed for two years. The published results, in the Journal of Clinical Endocrinology & Metabolism, found that men receiving TRT showed sustained improvements in sexual activity, hypogonadal symptoms, and sexual desire compared with placebo. Erectile function did not improve significantly relative to placebo, a finding that has been consistent across the testosterone trial literature [2].
This is the data signal the FDA is responding to. A large, well-controlled trial showed that in middle-aged and older men with low testosterone and low libido, two years of testosterone therapy produced measurable improvement in sexual desire and activity. Earlier work from the Testosterone Trials, published in the New England Journal of Medicine in 2016, had shown similar short-term benefits in older men [3]. The TRAVERSE results extended the evidence base to longer follow-up and addressed cardiovascular safety in the same population.
It is worth being precise about what the evidence does and does not establish. TRT in hypogonadal men with low libido improves desire and activity. It does not reliably improve erectile function. It does not appear to increase major adverse cardiovascular events over two to four years of follow-up in the populations studied. It does increase hematocrit, a known and monitored complication of testosterone therapy, which is one of several reasons that elevated hematocrit, a known and monitored complication of testosterone therapy, requires ongoing laboratory surveillance during treatment.
Considering a Testosterone Evaluation in North Carolina?
Comprehensive psychiatric evaluations include screening for hormonal contributors to mood, energy, and libido. If you are a North Carolina resident and want to be properly worked up rather than reflexively prescribed:
What Did Not Change on April 16
Several important things did not change with the FDA announcement, and conflating the announcement with an approval would mislead patients in ways that matter clinically.
The current approved indications for TRT remain unchanged. Men without an identified structural or genetic cause of hypogonadism are still, formally, outside the labeled indication. Insurance coverage decisions, which often track FDA-approved indications, have not changed. Off-label prescribing has not been formally endorsed by the agency, and any clinician prescribing in this space continues to carry the standard professional responsibilities that come with off-label use.
The class-wide labeling changes the FDA implemented in February 2025 also remain in effect. Those updates strengthened communication of cardiovascular safety considerations, abuse potential, and appropriate prescribing patterns. The April 2026 announcement does not soften any of those warnings. If anything, an expanded indication would likely come paired with renewed emphasis on patient selection, monitoring requirements, and risk communication.
What also did not change is the underlying biology of who actually has hypogonadism. Many men presenting to clinics with fatigue, low libido, and low mood do not have low testosterone when measured properly. About 30 percent of men whose initial testosterone measures in the hypogonadal range will have normal levels when retested, which is why the standard of care requires two morning measurements before a diagnosis is made. The Endocrine Society guideline emphasizes that hypogonadism is a clinical-plus-biochemical diagnosis: symptoms alone are not sufficient, and a single low number is not sufficient [4].
Why Sound Workup Matters More, Not Less, After This Announcement
It is tempting to read regulatory openness as license for looser practice. The opposite is true. As the candidate population for TRT widens, the importance of distinguishing real hypogonadism from low-normal testosterone with overlapping symptoms increases, not decreases. Many of the symptoms that drive men to seek testosterone evaluation (fatigue, low motivation, low libido, depressed mood, sleep disruption) are also the cardinal symptoms of major depressive disorder, generalized anxiety, sleep apnea, hypothyroidism, untreated diabetes, and chronic stress.
A proper workup for suspected hypogonadism includes two early-morning measurements of total testosterone using a CDC-certified or accuracy-validated assay, free testosterone (calculated or measured by equilibrium dialysis) when sex hormone-binding globulin status is in question, luteinizing hormone and follicle-stimulating hormone to distinguish primary from secondary hypogonadism, prolactin, and screening labs that include hematocrit, lipids, fasting glucose or hemoglobin A1c, prostate-specific antigen for men over 40, and thyroid function. When secondary hypogonadism is identified, additional pituitary evaluation may be warranted.
Equally important is the differential diagnosis. Low testosterone and depressive symptoms often travel together, but they do not always have a causal relationship in the direction patients assume. Depression itself can suppress hypothalamic-pituitary-gonadal axis function and produce low testosterone readings. In those cases, treating the depression often restores testosterone levels without exogenous hormone administration. The opposite can also be true. Low testosterone in some men contributes meaningfully to mood and motivational symptoms that look like depression but respond to hormonal correction rather than to antidepressants.
Distinguishing these clinical pictures requires history, examination, longitudinal observation, and time. Time is exactly what is in shortest supply in conventional rushed appointment models. This is one of the reasons a cash-pay practice that allows for the longer evaluation time this kind of workup requires can be a better fit for patients who want a proper assessment rather than a 15-minute lab interpretation.
Why a Psychiatrist Is Writing About This
Testosterone therapy has historically lived primarily in the domain of urology and endocrinology. The reason psychiatrists are increasingly part of this conversation is that the symptoms that drive men to seek hormonal evaluation are predominantly psychiatric in presentation. Low mood, low motivation, anhedonia, irritability, anxiety, sleep disturbance, and decreased libido are the symptom set that brings most men into a psychiatric office. The same symptom set is what brings men into a men’s health clinic asking about testosterone.
A psychiatrist who is comfortable with the hormonal differential can hold both possibilities at once. Is this a primary mood disorder? Is this hypogonadism presenting as a mood disorder? Is this both? Is the apparent low testosterone secondary to depression, sleep apnea, opioid use, or weight gain that itself needs to be addressed first? These questions are not abstract. They determine whether the right treatment is a selective serotonin reuptake inhibitor, a structured weight loss intervention, a sleep study, testosterone replacement, or some combination across time.
The April 2026 FDA announcement is part of a larger pattern of regulatory acceleration in psychiatric and adjacent medicine. Another recent regulatory shift in psychiatric and hormonal medicine has been the federal acceleration of psychedelic-assisted therapy review, which similarly opens treatment pathways that did not exist a decade ago. Both trends point in the same direction: the categories of “approved” and “off-label” are moving, and patients deserve clinicians who can read the evidence carefully rather than chase headlines.
For North Carolina men who suspect hormonal contributors to their symptoms, the practical question is where to be evaluated. Comprehensive testosterone replacement therapy in Wilmington, NC through Baghel Psychiatry includes the workup described above, integrated with assessment for psychiatric and lifestyle contributors. Patients with confirmed hypogonadism who are appropriate candidates can be initiated on TRT with appropriate monitoring; patients whose symptoms are better explained by another condition are treated for that condition instead.
What Happens Next in the Regulatory Process
The April 30, 2026 deadline is for sponsors to initiate contact with the FDA, not to submit a complete supplemental NDA. After initial contact, sponsors and the agency will discuss what additional clinical data the FDA requires to support the proposed new indication. Depending on whether existing data is judged adequate or whether new trials are needed, an actual approval could come in 12 to 36 months, or longer. Some sponsors may decline to pursue the new indication for commercial reasons, particularly if their patent life is short or their market position is weak.
If and when an indication is approved, the practical effect on prescribing will be significant but not transformative. Off-label prescribing for low libido in men with low normal or low testosterone has been common in men’s health clinics for years. An approved indication would shift this practice into the formal labeled indication, which would matter for insurance coverage, for prescriber comfort in less specialized practices, and for patient counseling. It would not change the underlying clinical reality that careful diagnosis and ongoing monitoring are necessary.
For patients, the most useful response to the announcement is to understand what it does and does not mean today. It does not mean a prescription is suddenly available. It does mean that if symptoms are real and ongoing, getting properly evaluated now puts a patient in a better position to make informed decisions as the regulatory environment evolves. The relationship between testosterone levels and irritability, mood, and motivation is one piece of the broader hormonal picture that a comprehensive evaluation should address.
Frequently Asked Questions
Did the FDA approve testosterone for low libido on April 16, 2026?
No. The FDA invited drug sponsors holding approved testosterone products to contact the agency by April 30, 2026, to discuss submitting a supplemental New Drug Application for an expanded indication covering low libido in men with idiopathic hypogonadism. This is the start of a regulatory process. An actual approval, if it comes, would likely be 12 to 36 months away or longer, and would still require sponsors to submit clinical data that the FDA judges sufficient to support safety and effectiveness for the new use.
What is idiopathic hypogonadism?
Idiopathic hypogonadism describes men with low serum testosterone and consistent clinical symptoms but no identifiable structural, genetic, or disease-based cause. The hypothalamus, pituitary, and testes all appear normal on workup, yet testosterone is low. This contrasts with classical hypogonadism, where a specific cause such as Klinefelter syndrome, pituitary tumor, prior chemotherapy, or testicular injury is identified.
Can I get prescribed TRT today if my testosterone is low and I have low libido?
It depends on the underlying cause. If a structural or genetic cause of hypogonadism is identified, TRT prescribing is within the current FDA-approved indication. If no cause is identified (idiopathic hypogonadism), prescribing TRT for low libido is currently off-label, which means it can be done legally and ethically by appropriate clinicians but is not formally endorsed by FDA labeling. The April 2026 announcement does not change this. A proper evaluation determines which category applies.
What is the difference between low testosterone and idiopathic hypogonadism?
Low testosterone is a single laboratory finding. Idiopathic hypogonadism is a clinical diagnosis that requires both consistently low testosterone on repeated morning measurements and clinical symptoms consistent with hypogonadism, after a workup has excluded identifiable causes. Many men with a single low testosterone reading do not actually have hypogonadism on retesting. The diagnosis requires a complete clinical and biochemical assessment, not a single lab number.
What does a proper testosterone workup include?
A complete workup includes two early-morning measurements of total testosterone using an accurate assay, free testosterone calculation or direct measurement when indicated, luteinizing hormone and follicle-stimulating hormone to distinguish primary from secondary hypogonadism, prolactin, hematocrit, lipids, fasting glucose or hemoglobin A1c, thyroid function, and prostate-specific antigen for men over 40. The history should screen for sleep apnea, opioid use, weight changes, alcohol use, and depression, all of which can suppress testosterone. When secondary hypogonadism is identified, additional pituitary evaluation may be needed.
How does this affect insurance coverage of testosterone therapy?
The April 2026 announcement does not change current insurance coverage. Coverage decisions typically track FDA-approved indications, so off-label prescribing for idiopathic hypogonadism remains less likely to be covered than prescribing for classical hypogonadism with an identified cause. If and when the FDA approves an expanded indication, insurance coverage policies may eventually update to match, though insurer policies are independent of FDA action and lag behind regulatory changes.
Why is a psychiatrist evaluating testosterone-related symptoms?
The symptoms that drive most men to seek testosterone evaluation, such as low mood, low motivation, fatigue, irritability, sleep disturbance, and decreased libido, overlap substantially with the symptoms of major depressive disorder, anxiety disorders, and sleep disorders. A psychiatrist who is comfortable with hormonal evaluation can distinguish primary mood disorders from hypogonadism presenting as a mood disorder, and can hold both possibilities open during evaluation. Treatment paths differ depending on the answer.
Should I get my testosterone tested after the military’s announcement?
If you have symptoms, especially low libido, reduced morning erections, low mood, or fatigue that nothing else explains, it’s reasonable to get tested. The way it’s done matters more than whether it’s done. Ask for a fasting morning total testosterone drawn before 10 a.m., interpreted with free testosterone, LH, and FSH when the picture warrants it. A single number from a random afternoon draw isn’t a diagnosis, and it isn’t a reason to start treatment.
Can low testosterone cause depression, or is it the other way around?
The two overlap and the arrow points both ways. Men with depression more often have low testosterone, and low testosterone can worsen mood and drive. Testosterone isn’t a treatment for depression on its own. The trial evidence shows only a small effect, larger at higher doses. For a man with a confirmed low level and depressive symptoms, treating the deficiency can help the mood symptoms. For a man with normal testosterone, low mood is a different problem and needs its own treatment.
Get a Comprehensive Evaluation in North Carolina
Whether the answer is testosterone, an antidepressant, a sleep study, or none of the above, the right starting point is a thorough psychiatric and hormonal evaluation rather than a quick lab interpretation. Baghel Psychiatry provides cash-pay telehealth psychiatric evaluations across North Carolina, with appropriate hormonal workup integrated into the clinical assessment. Initial evaluations are 45 to 60 minutes.
Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects publicly available regulatory announcements and published clinical literature as of April 2026 and is not a substitute for personalized medical evaluation. Testosterone replacement therapy carries clinical risks that require individualized assessment and ongoing monitoring. If you are considering hormonal evaluation or treatment, consult a qualified physician who can review your history, examination findings, and laboratory results in context.
References
1. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. PMID: 37326322
2. Pencina KM, Travison TG, Cunningham GR, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569-580. PMID: 37589949
3. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521
4. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
5. U.S. Food and Drug Administration. FDA Takes Step Forward on Testosterone Therapy for Men. April 16, 2026. Press release.
6. U.S. Food and Drug Administration. Potential New Indication for Testosterone Replacement Therapy. Federal Register. April 20, 2026. Docket No. FDA-2025-N-6743. Federal Register notice.
7. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. PMID: 20554979
8. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. PMID: 30427999
9. Toropin K, Perrone M. Hegseth announces new policy to test troops for low testosterone. Associated Press. July 15, 2026. News report.
10. PBS NewsHour. Hegseth announces new policy to test troops for low testosterone and offer them hormone replacement therapy. July 15, 2026. News report.